• Cuban picks up 5 more brand-name drugs

    Billionaire and Shark Tank investor Mark Cuban will soon start selling five Pfizer brand-name drugs through his pharmaceutical company, Mark Cuban Cost Plus Drug Co. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • Why big PBMs form GPOs

    Following the Federal Trade Commission's expanded probe into pharmacy benefit managers and their group purchasing organizations, Drug Channels listed five possible reasons why PBMs create GPOs.
  • Cuban's pharmacy drops 18 prices

    Mark Cuban Cost Plus Drug Co. lowered prices for 18 drugs May 23, according to a company tweet. 
  • RSV, pneumonia drug falls into shortage

    There is not enough supply for usual ordering of ribavirin inhalation solutions, a drug for severe pediatric pneumonia cases caused by respiratory syncytial virus, according to a May 23 post from the American Society of Health-System Pharmacists. 
  • FDA approves drug for hospital-acquired pneumonia

    On May 23, the FDA approved a new drug intended to treat hospital-acquired pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus, a critical bacterial pathogen. 
  • AHA, ASHP oppose 340B bill set for markup

    The American Hospital Association and American Society of Health-System Pharmacists, along with four other groups, recently sent a letter to the House Energy and Commerce Committee's Health Subcommittee opposing two bill amendments that would affect 340B hospitals and stakeholders.
  • Moderna buys biomanufacturing plant in Massachusetts; project expected to cost $322M

    Moderna has purchased a new biomanufacturing facility in Marlborough, Mass., which will be designated for mRNA manufacturing. It is anticipated to open in September 2024, according to an April 28 report from the Worcester Business Journal. 
  • Ozempic pill results in 15% weight loss: Novo Nordisk

    A pill version of Ozempic (semaglutide), a Type 2 diabetes drug in high demand for its off-label use for weight loss, resulted in 15.1 percent weight loss among phase 3 study participants. 
  • 30 OTC health products recommended by pharmacists

    In U.S. News' newest over-the-counter medicine and health products ranking, the news organization collaborated with The Harris Poll to determine what 350 pharmacists recommend among more than 700 products. 
  • Top PBMs by 2022 market share

    One pharmacy benefit manager makes up one-third of the market, according to a May 23 report from Drug Channels. 
  • Teva to cut back on generic manufacturing

    Teva Pharmaceuticals said it will shrink some of its generic drug manufacturing as the Israel-based drugmaker reports $20.7 billion in debt. 
  • ASHP launches national pharmacy technician group

    The American Society of Health-System Pharmacists has announced the inaugural launch of a national membership organization aimed at supporting and advocating for policies that advance the role of pharmacist technicians in patient care.
  • FDA approves 1st drug for rare skin condition

    The FDA on May 19 approved the first drug to treat patients with dystrophic epidermolysis bullosa — a rare genetic disorder that causes fragile skin and persistent sores. 
  • Optum COO moves to Corewell Health pharmacy position

    Corewell Health, based in Grand Rapids and Southfield, Mich., named Jason McCarthy, PharmD, as its next chief pharmacy officer May 17. 
  • What could happen if Medicare covered weight loss drugs?

    A 2003 law prohibits Medicare Part D from covering weight loss drugs, but if that changes, this class of popular medications could cost Medicare tens of billions, the KFF reported May 18. 
  • US drugmaker to close July 1

    A Buffalo, N.Y.-based biopharmaceutical company filed for bankruptcy and is attempting to sell its assets before a July 1 shutdown, according to court documents. 
  • FTC expands PBM probe

    The Federal Trade Commission is widening its inquiry into the pharmacy benefit manager industry to include two group purchasing organizations that negotiate drug rebates on behalf of PBMs. 
  • 340B reporting mandate approved by House subcommittee, legislation moves forward

    Legislation proposing transparency and oversight of the 340B drug discount program was passed May 17 by the House Energy and Commerce Committee's Subcommittee on Health. The bill, H.R. 3290, will now advance to the full Energy and Commerce Committee.
  • Chemo drug shortage could lead to 'inferior care': American Cancer Society

    The shortage of several generic forms of chemotherapy drugs used to treat breast, ovarian, lung and bladder cancers, among others, have risen to the level of what amounts to a "public health emergency," Amanda Fader, MD, a professor at the Johns Hopkins University School of Medicine and a president-elect of the Society of Gynecologic Oncology, said in a May 17 New York Times report. 
  • Tallahassee Memorial Hospital taps into emergency supplies amid cancer drug shortage

     Tallahassee (Fla.) Memorial Hospital is going through emergency supplies amid a national drug shortage to continue chemotherapy treatments for cancer patients, according to a May 15 report from WFSU. 

Featured Whitepapers

Featured Webinars